Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.
作者： Mellar Davis
DOI: 10.2165/00003088-200746100-00002
关键词:
摘要: A class of endogenous Opioids is upregulated in liver disease particular to cholestasis, which contributes symptoms such as pruritus, hypotension and encephalopathy. Symptoms associated with cholestasis are reversed or at least ameliorated by μ opioid receptor antagonists. Palliation related cholestatic also involves bile acid binding agents. Opioid antagonists, unlike agents, have been reported relieve multiple symptoms, except for improve function demonstrated experimental cholestasis. Exogenous pharmacology altered disease. Dose reduction prolongation dose intervals necessary depending on the severity
springer.com
sci-hub.se 参考文章(200)
E. Tanaka, Clinical importance of non-genetic and genetic cytochrome P450 function tests in liver disease. Journal of Clinical Pharmacy and Therapeutics. ,vol. 23, pp. 161- 170 ,(1998) , 10.1046/J.1365-2710.1998.00135.X
F. Johnson, Janina Longtine, Nils Kucher, Hylton Joffe, Ruliang Xu, Samuel Goldhaber, Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thrombosis and Haemostasis. ,vol. 91, pp. 1123- 1128 ,(2004) , 10.1160/TH04-02-0083
U. Breyer-Pfaff, K. Nill, Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol. Journal of Pharmacy and Pharmacology. ,vol. 56, pp. 1601- 1606 ,(2010) , 10.1211/0022357045020
David M. Novick, Mary Jeanne Kreek, Patricia A. Ams, Lisa L. Lau, Stanley R. Yancovitz, Alvin M. Gelb, Effect of Severe Alcoholic Liver Disease on the Disposition of Methadone in Maintenance Patients Alcoholism: Clinical and Experimental Research. ,vol. 9, pp. 349- 354 ,(1985) , 10.1111/J.1530-0277.1985.TB05558.X
F.E.M. Murtagh, J.M. Addington-Hall, P. Donohoe, I.J. Higginson, Symptom management in patients with established renal failure managed without dialysis. EDTNA/ERCA journal (English ed.). ,vol. 32, pp. 93- 98 ,(2006) , 10.1111/J.1755-6686.2006.TB00459.X
Nora V Bergasa, Richard B Rothman, Erik Mukerjee, John Vergalla, E.Anthony Jones, Up-regulation of central mu–opioid receptors in a model of hepatic encephalopathy: A potential mechanism for increased sensitivity to morphine in liver failure Life Sciences. ,vol. 70, pp. 1701- 1708 ,(2002) , 10.1016/S0024-3205(02)01487-X
A. A. Somogyi, A. Menelaou, S. V. Fullston, CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement Xenobiotica. ,vol. 34, pp. 875- 887 ,(2004) , 10.1080/00498250400008371
Samir Ahboucha, Roger F. Butterworth, Role of endogenous benzodiazepine ligands and their GABA-A--associated receptors in hepatic encephalopathy. Metabolic Brain Disease. ,vol. 20, pp. 425- 437 ,(2005) , 10.1007/S11011-005-7928-Y
Michael S. Roberts, Beatrice M. Magnusson, Frank J. Burczynski, Michael Weiss, Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clinical Pharmacokinectics. ,vol. 41, pp. 751- 790 ,(2002) , 10.2165/00003088-200241100-00005
Jean-Frédéric Westphal, Jean-Marie Brogard, Drug Administration in Chronic Liver Disease Drug Safety. ,vol. 17, pp. 47- 73 ,(1997) , 10.2165/00002018-199717010-00004